Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer

World Journal of Surgical Oncology

Ming Zongjuan¹  Zhang Wei²  Li Wei¹  Yang Shuanying¹  Rong Biaoxue¹ 

[1] Department of Respiratory Medicine, The Second Affiliated Hospital of Xi’an Jiaotong University, 157 Xi-Wu Road, Xi’an, Shaanxi, 710004, China;Department of Thoracic Surgery, The Second Affiliated Hospital of Xi’an Jiaotong University, 157 Xi-Wu Road, Xi’an, Shaanxi, 710004, China

关键词: Meta-analysis;    First-line chemotherapy;    Lung cancer;    YH-16;    Endostar;    Recombinant human endostatin;   

Others  :  827376
DOI  :  10.1186/1477-7819-10-170

 received in 2012-03-14, accepted in 2012-07-27,  发布年份 2012

【 摘 要 】

Background

Many studies have investigated the efficacy of Endostar combined with platinum-based doublet chemotherapy (PBDC) versus PBDC alone for treating advanced non-small cell lung cancer (NSCLC). This study is a meta-analysis of available evidence.

Methods

Fifteen studies reporting Endostar combined with PBDC versus PBDC alone for treating advanced NSCLC were reviewed. Pooled odds ratios and hazard ratio with 95% confidence intervals were calculated using either the fixed effects model or random effects model.

Results

The overall response rate (ORR) and disease control rate (DCR) of Endostar combined with PBDC for treating NSCLC were significantly higher than those of PBDC alone, with 14.7% and 13.5% improvement, respectively (P < 0.00001). In addition, the time to progression (TTP) and quality of life (QOL) were improved after the treatment of Endostar combined with PBDC (P < 0.00001). The main adverse effects found in this review were hematological reactions, hepatic toxicity, and nausea/vomiting. Endostar combined with PBDC had a similar incidence of adverse reactions compared with PBDC alone (P < 0.05).

Conclusions

Endostar combined with PBDC was associated with higher RR, DCR, and TTP as well as superior QOL profiles compared with PBDC alone. Endostar combined with PBDC had a similar incidence of adverse reactions compared with PBDC alone.

【 授权许可】

   
2012 Biaoxue et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156.
• [2]Novello S, Le Chevalier T: Chemotherapy for non-small-cell lung cancer. Part 1: Early-stage disease. Oncology (Williston Park, NY) 2003, 17:357-364.
• [3]Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001, 19:3210-3218.
• [4]Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
• [5]Novello S, Pimentel FL, Douillard JY, O’Brien M, von Pawel J, Eckardt J, Liepa AM, Simms L, Visseren-Grul C, Paz-Ares L: Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with advanced non-small cell lung cancer. J Thorac Oncol 2010, 5:1602-1608.
• [6]O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
• [7]Song H, Liu X, Zhang H, Zhu B, Yuan S, Liu S, Tang Z: Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys. Acta Pharmacol Sin 2005, 26:124-128.
• [8]Ling Y, Yang Y, Lu N, You Q, Wang S, Gao Y, Chen Y, Guo QL: Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 2007, 361:79-84.
• [9]Cao H, Liu JP, Lewith GT: Traditional Chinese Medicine for treatment of fibromyalgia: a systematic review of randomized controlled trials. J Altern Complement Med 2010, 16:397-409.
• [10]Cirocchi R, D’Ajello F, Trastulli S, Santoro A, Di Rocco G, Vendettuoli D, Rondelli F, Giannotti D, Sanguinetti A, Minelli L, Redler A, Basoli A, Avenia N: Meta-analysis of thyroidectomy with ultrasonic dissector versus conventional clamp and tie. World J Surg Oncol 2010, 8:112. BioMed Central Full Text
• [11]Wang J, Sun Y, Liu Y, Yu Q, Zhang Y, Li K, Zhu Y, Zhou Q, Hou M, Guan Z: Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi 2005, 8:283-290.
• [12]Yang L, Wang JW, Cui CX, Hang J, Zang HP, Li ST, Sun Y: Rh-endostatin(YH-16) in combination with vinorelbine and cisplatin for advanced non-small cell lung cancer:a multicenter phase II trial. Chin J New Drugs 2005, 14:204-207.
• [13]Cai L, Sun LC, Yang CY, Men QW, Pang H, Sui GJ: Observation on the efficacy of endostar combined with Chemotherapy in the treatment of non-small cell lung cancer. Chinese J Pract Int Med 2007, 27:1541-1542.
• [14]Mu HY, Shen CY, Feng YL: Clinical observation on the target therapy of rh-endostin, combined with chemotherapy in advanced non-small cell lung cancer. Zhongguo Fei ai Za Zhi 2009, 12:780-784.
• [15]Liao HY, Feng WN, Li Y, Zang J, Cai SW, Chen HG, Sun JP, Wei YM, Gu LJ: Study of the feasibility of endostar plus gemcitabine and cisplatin regimen for advanced non-small-cell lung cancer. Zhongguo Fei Ai Za Zhi 2009, 12:574-576.
• [16]Zhang T, Liu DH, Wang B, Li XY: Latest efficacy and safety of YH-16 combined with GP for advanced non-small cell lung cancer. Chin General Pract 2009, 12:969-971.
• [17]Liu J, Huang JZ, Quan JZ, Liu Y, Dong MX: Clinical study of concurrent chemoradiotherapy combined with YH-16 in the treatment of local advanced non-small cell lung cancer. Chin Med Herald 2009, 6:253-254.
• [18]Ma J, Yang J, Li Z, Li F, Huang D, Yan G, Wang J, Lang J: A randomized clinical trail of endostar combined with concurrent chemoradiotherapy in treatment of local advanced non-small cell lung cancer. J Clin Med Pract 2009, 13:20-21.
• [19]Shi GY, Su YH: The clinical observation of Endostar injection combined with GP regimen in advanced non-small cell lung cancer. Journal of Medical Forum 2009, 30:53-54.
• [20]Han B, Xiu Q, Wang H, Shen J, Gu A, Luo Y, Bai C, Guo S, Liu W, Zhuang Z: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol 2011, 6:1104-1109.
• [21]Zhao X, Mei K, Cai X, Chen J, Yu J, Zhou C, Li Q: A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer. Invest New Drugs 2011, 30:1144-1149.
• [22]Hu HT, Gong CM, Zeng LJ, Zhang T: Recombinant human endostatin combined with topotecan plus cisplatin regimen for advanced small-cell lung cancer. Journal of Regional Anatomy and Operative Surgery 2011, 20:190-191.
• [23]Wen F, Wang W, Shang LQ, Li XC, Liu JJ: Observation of short term effects of endostar combined with NP regimen for non-small cell lung cancer. Journal of Clinical Medicine in Practice 2011, 15:79-80.
• [24]Zhang H, Qi R: Clinical study of chemotherapy combined with endostar in the treatment of advanced non-small cell lung cancer. Journal of Xinjiang Medical University 2011, 34:533-535.
• [25]Chen Q, Xie Q, Shi Q, Xiao S: Short-term efficacy of YH-16 combined with GP regimen for advanced non-small cell lung cancer. Cancer Research on Prevention and Treatment 2011, 38:199-201.
• [26]Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
• [27]Zhuang HQ, Yuan ZY: Process in the mechanisms of endostatin combined with radiotherapy. Cancer Lett 2009, 282:9-13.
• [28]Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
• [29]Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27:1227-1234.
• [30]Sun Y, Wang J, Liu Y, Song X, Zhang Y, Li K, Zhu Y, Zhou Q, You L, Yao C: Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol (Meeting Abstracts) 2005, 23:7138.
• [31]Han B, Xiu Q, Wang H: 2008. J Clin Oncol (Meeting Abstracts) 2008, 26:19126.
• [32]Kabbinavar FF, Wallace JF, Holmgren E, Yi J, Cella D, Yost KJ, Hurwitz HI: Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. Oncologist 2008, 13:1021-1029.